Kapa Biosystems Extends Exclusive Japanese Distribution Agreement with Nippon Genetics
News Aug 04, 2014
Kapa Biosystems has signed a new three-year exclusive distribution agreement with Nippon Genetics Co., Ltd., further extending the successful seven-year relationship between the companies and enabling Nippon Genetics to continue marketing, distributing, and servicing Kapa Biosystems’ genomics reagents in Japan. This agreement is a key part of Kapa Biosystems corporate growth strategy and the first of several key commercial announcements that will be made later this year.
Kapa Biosystems offers a portfolio of advanced reagents for use in PCR, qPCR, next-generation sequencing, and molecular diagnostics applications. The reagents contain novel enzymes—engineered via directed evolution—that confer significant performance advantages when compared to traditional wild-type enzymes. Many of the products are optimized for challenging samples and high-throughput workflows, and include pre-validated scripts using the leading liquid-handling automation platforms.
“The genetic research and applied markets in Japan are growing exponentially and many scientists rely on us to deliver high-quality and reliable solutions,” said Kazuo Yamazaki, CEO and President, Nippon Genetics Co., Ltd. “Kapa Biosystems products fit perfectly within our innovative life science offerings and enable us to provide more complete solutions to our customers.”
Over the past year, Kapa Biosystems has added several proven industry veterans to its management team and more than doubled the company’s previous facility investment to scale enzyme production, quality control, and manufacturing capacity across its various business franchises. Over the next few months, the company plans on announcing several other key distribution agreements and corporate initiatives to better support the growing number of customers around the world.
“With more than 25 years of experience working with cutting edge technologies and strong relationships with the key opinion leaders in Japan, Nippon Genetics is the ideal distribution partner for our business,” said Jean-Christophe Hatinguais, Director of International Sales, Kapa Biosystems. “We are seeing broad adoption and strong demand for our innovative products not only in Japan, but across the Asia Pacific, European, and North American regions. We are now focused on extending our global reach by increasing our strategic investments and expanding our distribution network in key markets.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.